Company intelligence / Profile preview

Trinity Innovation Bioventure

Singapore, Singaporetrinity-fund.com.sg ↗

Ownership: Private
Development stage: Other

Overview

Trinity Innovation Bioventure Singapore (TIBS) is an investor/incubator focused on early-stage Asian/global biotech innovation addressing major health challenges. It has invested at least $15M seed into Axcynsis Therapeutics.

Therapeutic areas: OncologyRare Diseases
Modalities: Small moleculeMonoclonal antibodyGene therapy
Industry: Investors

Partnerships

Synergy with "Trinity Innovation Fund" for access to China market and regional resources

Beyond the preview

Go deeper on Trinity Innovation Bioventure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trinity Innovation Bioventure.

Explore the full profile